EUROIMMUN Logo
Find
X

What are you looking for?

Filter for products in our complete portfolio

Product finder

Worldwide
X
EUROIMMUN worldwide

This website provides an overview of the business activities and products of EUROIMMUN AG worldwide. Not all products are registered and approved in all countries or regions. Please contact your country representative for product availability and information

EUROIMMUN branches

Choose your country

Europe

North America

South & Central America

Asia

Middle East & Africa

EUROIMMUN Logo
Product finder

Autoimmune dermatoses

Clinical information

Bullous autoimmune dermatoses are rare, blister-forming diseases of the outer skin and the adjacent mucous membranes. They are characterised by the formation of autoantibodies against structural proteins of the skin. These structural proteins establish the cell-to-cell contact in keratinocytes within the epidermis and the adhesion of the epidermis to the dermis. Bullous autoimmune dermatoses are divided into four main groups based on their target antigens and the localisation of the blisters:

  • Pemphigus diseases: desmoglein 1 (Dsg1), desmoglein 3 (Dsg3), different plakins (mostly envoplakin)
  • Pemphigoid diseases: BP180, BP230, laminin 332, P200
  • Epidermolysis bullosa acquisita: collagen type VII
  • Dermatitis herpetiformis: endomysium (tissue/epidermal transglutaminase), deamidated gliadin peptides (GAF-3X)

Diagnostics

A conclusive diagnosis of blister-forming autoimmune dermatoses requires the detection of both tissue-bound autoantibodies by direct immunofluorescence and circulating autoantibodies. The circulating specific autoantibodies against epidermal antigens (prickle cell desmosomes and epidermal basement membrane) in patient serum are detected using the indirect immunofluorescence test (IIFT) with tissue sections of primary oesophagus (or tongue). For further differentiation of autoantibodies against basement membrane structures, tissue sections of primate salt-split skin are used. Final diagnosis is based on a combination of the clinical picture with the detection of autoantibodies against the individual target antigens using IIFT, monospecific ELISA or immunoblot analyses.

Patients who suffer from bullous pemphigoid (BP) exhibit autoantibodies against BP180 and frequently also against BP230. The serum level of autoantibodies against BP180 correlates with the disease activity of BP, the serum level of autoantibodies against BP230 with the duration of the disease. Hence, the Anti-BP180-NC16A-4X ELISA (IgG) and the Anti-BP230-CF ELISA (IgG) are not only suited to reliably serologically identifying BP, but also to monitoring the activity of the disease before and during treatment and assessing the disease duration. Autoantibodies against desmoglein 1 and 3 are markers for pemphigus diseases. IIFT has proven valuable for detecting circulating autoantibodies in pemphigus. ELISA using recombinant desmoglein 1 and 3 offer the same sensitivity and specificity as IIFT. The anti-Dsg1 and -Dsg3 antibody levels measured correlate to a large extend with the severity and activity of the disease and the therapy success. The determination of autoantibodies against envoplakin contributes to diagnosis of PNP as well as differential diagnostic clarification. The determination of autoantibodies against collagen type VII confirms the diagnosis of EBA and enables the delimitation from other bullous autoimmune dermatoses.

Files

Autoimmune bullous dermatoses

Serological diagnosis of bullous autoimmune dermatoses

Diagnosis of mucous membrane pemphigoid

Products

Filter techniques:

Method
Parameter
Substrate
Species
ELISA
Dermatology Profile (BP180-NC16A-4X,
BP230-CF, desmoglein 1, desmoglein 3,
envoplakin, collagen type VII separately)
antigen-coated
microplate wells
Details
ELISA
envoplakin
antigen-coated
microplate wells
Details
ELISA
desmoglein 1
antigen-coated
microplate wells
Details
ELISA
desmoglein 3
antigen-coated
microplate wells
Details
IIFT
antibodies against epidermis: desmosomes
(pemphigus vulgaris control)
Details
IIFT
epidermis:
prickle cell desmosomes
epidermal basement membrane
oesophagus
monkey
Details
IIFT
Dermatology Screen (EM) EUROPattern
epidermis:
prickle cell desmosomes
epidermal basement membrane

oesophagus

monkey
Details
IIFT
Dermatology Mosaic 20
epidermis
pemphigoid antigens
2 BIOCHIPs per field:
oesophagus
salt-split skin

monkey
monkey
Details
IIFT
Dermatology Mosaic 20 EUROPattern
epidermis
pemphigoid antigens
2 BIOCHIPs per field:
oesophagus
salt-split skin

monkey
monkey
Details
IIFT
Dermatology Mosaic 7
epidermis
pemphigoid antigens
BP230gC
desmoglein 1
desmoglein 3
BP180-NC16A-4X
6 BIOCHIPs per field:
oesophagus
salt-split skin
transfected cells
transfected cells
transfected cells
BP180-NC16A-4X BIOCHIPs

monkey
monkey
EU 90
EU 90
EU 90
Details
IIFT
EUROPLUS Dermatology Mosaic 7 EUROPattern
epidermis
pemphigoid antigens
BP230gC
desmoglein 1
desmoglein 3
BP180-NC16A-4X
6 BIOCHIPs per field:
oesophagus
salt-split skin
transfected cells
transfected cells
transfected cells
BP180-NC16A-4X EUROPLUS

monkey
monkey
EU 90
EU 90
EU 90
Details
IIFT
antibodies against epidermis: basement membrane
(bullous pemphigoid control)
Details
ELISA
BP230-CF
antigen-coated
microplate wells
Details
ELISA
BP180-NC16A-4X
antigen-coated
microplate wells
Details
IIFT
laminin 332 (LAM332)
transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
Details
ELISA
collagen type VII
antigen-coated
microplate wells
Details
Show all products
Back to top
Contact person on site
Please click on a country or enter yours
North America
South & Central America
Europe
Asia
Oceania
Middle East & Africa